Overview of the use of CoQ10 in cardiovascular disease

BioFactors

Volumn 9, Issue 2-4, 1999, Pages 273-284

  Langsjoen, Peter H ^a   Langsjoen, Alena M ^a  

^a NONE   (United States)

Author keywords

Angina; Cardiac surgery; Cardiovascular disease; Coenzyme Q10; Diastolic dysfunction; Heart failure; HMG CoA reductase inhibitors; Hypertension; Ischemia; Ubiquinone

Indexed keywords

UBIDECARENONE; ANTIOXIDANT; DRUG DERIVATIVE; UBIQUINONE;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS SURGERY; DRUG EFFECT; DRUG SCREENING; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; REVIEW; CORONARY ARTERY BYPASS GRAFT; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; REPERFUSION INJURY;

ANGINA;

ANTIOXIDANTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; CORONARY ARTERY BYPASS; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; MYOCARDIAL ISCHEMIA; REPERFUSION INJURY; UBIQUINONE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0032588768     PISSN: 09516433     EISSN: None     Source Type: Journal    
DOI: 10.1002/biof.5520090224     Document Type: Review

References (93)

1. R. Aejmelaeus, T. Metsä-Ketelä, P. Laippala, H. Alho and T. Solakvi, Ubiquinol-10 and total peroxyl radical trapping capacity of LDL lipoproteins during aging: the effects of Q-10 supplementation, Molecular Aspects of Medicine 18(Suppl.) (1997), s113-s120.
2. 10 content, Molecular Aspects of Medicine 18(Suppl.) (1997), s105-s112.
3. 10 Drug Surveillance Investigators, Molecular Aspects of Medicine 15(Suppl.) (1994), s287-s294.
4. 10 preserves plasma ubiquinone levels in patients treated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, Int. J. Clin. Lab. Res. 24(3) (1994), 171-176.
5. R.F. Beyer and L. Ernster, The antioxidant role of coenzyme Q, in: Highlights in Ubiquinone Research, G. Lenaz, O. Barnabei, A. Rabbi and M. Battino, eds, Taylor and Francis, London, 1990, pp. 191-213.
6. 10 from myocardial reperfusion injury during coronary artery bypass grafting, Ann. Thorac. Surg. 58(5) (1994), 1427-1432.
7. 10 of tissue reperfusion injury during abdominal aortic cross-clamping, J. Cardiovasc. Surg. (Torino) 37(3) (1996), 229-235.
8. 10 on myocardial preservation during hypothermic cardioplegic arrest, J. Thorac. Cardiovasc. Surg. 107(1) (1994), 242-247.
9. A. Constantinescu, J.J. Maguire and L. Packer, Interactions between ubiquinones and vitamins in membranes and cells, Molecular Aspects of Medicine 15(Suppl.) (1994), s57-s65.
10. F.L. Crane, Y. Hatefi, R.I. Lester and C. Widmer, Isolation of a quinone from beef heart mitochondria, Biochim. Biophys. Acta 25 (1957), 2201.
11. F.L. Crane and D.J. Morrè, Evidence for coenzyme Q function in Golgi membranes, in: Biomedical and Clinical Aspects of Coenzyme Q, K. Folkers and Y. Yamamura, eds, Elsevier, Amsterdam, 1977, pp. 3-14.
12. F.L. Crane, I.L. Sun, R. Barr and D.J. Morrè, Coenzyme Q in Golgi apparatus membrane redox activity and proton uptake, in: Biomedical and Clinical Aspects of Coenzyme Q, K. Folkers and Y. Yamamura, eds, Vol. 4, Elsevier, Amsterdam, 1984, pp. 77-86.
13. 10 pretreatment, J. Thorac. Cardiovasc. Surg. 111(2) (1996), 443-450.
14. 10 in essential hypertension, Molecular Aspects of Medicine 15(Suppl.) (1994), s257-s263.
15. L. Ernster and P. Forsmark-Andree, Ubiquinol: an endogenous antioxidant in aerobic organisms, K. Folkers, S.A. Mortensen, G.P. Littarru, T. Yamagami and G. Lenaz, eds, The Clinical Investigator 71(8) (1993), S60-S65.
16. 10 in human heart disease, Int. Z. Vitaminforsch 40(3) (1970), 380-390.
17. 10, Proc. Natl. Acad. Sci. USA 82(3) (1985), 901-904.
18. K. Folkers, P.H. Langsjoen, R. Willis, P. Richardson, L.J. Xia, C.Q. Ye and H. Tamagawa, Lovastatin decreases coenzyme Q levels in humans, Proc. Natl. Acad. Sci. USA 22(87) (1990), 8931-8934.
19. 10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study, J. Clin. Pharmacol. 33(3) (1993), 226-229.
20. 10 level and myocardial contractility in hypertensive patients, in: Biomedical and Clinical Aspects of Coenzyme Q, Vol. 4, Elsevier, Amsterdam, 1984, pp. 263-270.
21. K. Hashiba, K. Kuramoto, Z. Ishimi, K. Kato, K. Seki, K. Taniguchi, T. Taya, F. Terawasa, S. Torii, J. Fijii, N. Yamazaki and H. Watanabe, Heart 4 (1972), 1579-1589 (in Japanese).
22. 10 on exercise tolerance in patients with stable angina pectoris, in: Biomedical and Clinical Aspects of Coenzyme Q, K. Folkers and Y. Yamamura, eds, Vol. 4, Elsevier, Amsterdam, 1984, pp. 291-301.
23. K.U. Ingold, V.W. Bowry, R. Stocker and C. Walling, Autoxidation of lipids and antioxidation by alpha-tocopherol and ubiquinol in homogeneous solution and in aqueous dispersions of lipids: unrecognized consequences of lipid particle size as exemplified by oxidation of human low density lipoprotein, Proc. Natl. Acad. Sci. USA 90(1) (1993), 45-49.
24. T. Iwabuchi, N. Kato, N. Goto, Y. Higuchi, S. Takaola, Y. Iwaki, E. Shidara, M. Yoshimura and J. Atarashi, Jpn. J. Clin. Exp. Med. 49 (1972), 2604-2608 (in Japanese).
25. W.V. Judy, J.H. Hall, P.D. Toth and K. Folkers, Double blind-double crossover study of coenzyme Q10 in heart failure, in: Biomedical and Clinical Aspects of Coenzyme Q, K. Folkers and Y. Yamamura, eds, Vol. 5, Elsevier, Amsterdam, 1986, pp. 315-323.
26. 10 treated congestive heart failure patients compared to conventionally treated patients, in: Biomedical and Clinical Aspects of Coenzyme Q, K. Folkers, G.P. Littarru and T. Yamagami, eds, Vol. 6, Elsevier, Amsterdam, 1991, pp. 291-298.
27. 10 during heart surgery, Clinical Investigator 71(8) (1993), S155-S161.
28. 10 on exercise tolerance in chronic stable angina pectoris, American Journal of Cardiology 56 (1985), 247-251.
29. 10 in patients with ischemic heart disease, Int. J. Clin. Pharmacol. Ther. Toxicol. 28(3) (1990), 123-126.
30. 10 and relationship to oral dosage, in: Biomedical and Clinical Aspects of Coenzyme Q, K. Folkers and Y. Yamamura, eds, Vol. 3, Elsevier, North-Holland Press, 1981, pp. 67-89.
31. 10 in patients with cardiac failure, in: Biomedical and Clinical Aspects of Coenzyme Q, K. Folkers and Y. Yamamura, eds, Vol. 4, Elsevier, Amsterdam, 1984, pp. 243-252.
32. 10 and antioxidants in acute myocardial infarction, Molecular Aspects of Medicine 15(Suppl.) (1994), s143-s147.
33. R. Laaksonen, K. Jokelainen, T. Sahi, M.J. Tikkanen and J.J. Himberg, Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans, Clin. Pharmacol. Ther. 57(1) (1995), 62-66.
34. 10, Proceedings of the National Academy of Sciences USA 82 (1985), 4240-4244.
35. 10 therapy for idiopathic dilated cardiomyopathy, American Journal of Cardiology 65(7) (1990), 521-523.
36. 10 treatment, K. Folkers, S.A. Mortensen, G.P. Littarru, T. Yamagami and G. Lenaz, eds, Clinical Investigator 71 (1993), S140-S144.
37. 10 in clinical cardiology: a long-term study, Molecular Aspects of Medicine 15(Suppl.) (1994), s165-s175.
38. 10, The Molecular Aspects of Medicine 15(Suppl.) (1994), s265-s272.
39. 10, Molecular Aspects of Medicine 18(Suppl.) (1997), s145-s151.
40. 10 in the elderly, in: Anti-Aging Medical Therapeutics, R.M. Klatz and R. Goldman, eds, Health Quest Publications, 1997, pp. 113-120.
41. A. Lawen, R.D. Martinius, G. McMullen, P. Nagley, F. Vaillant, E.J. Wolvetang and A.W. Linnane, The universality of bioenergetic disease: The role of mitochondrial mutation and the putative inter-relationship between mitochondria and plasma membrane NADH oxidoreductase, Molecular Aspects of Medicine 15 (1994), s13-s27.
42. G. Lenaz and G. Parenti Castelli, Biological Membranes, G. Benga, ed., Vol. 1, CRC Press, Boca Raton, USA, 1984, pp. 93-136.
43. G. Lenaz and D. Esposti, Physical properties of ubiquinones in model systems and membranes, in: Coenzyme Q. Biochemistry, Bioenergetics and Clinical Applications of Ubiquinone, G. Lenaz, ed., John Wiley & Sons, 1985, Chapter IV, pp. 83-105.
44. G. Lenaz, The role of mobility of redox components in the inner mitochondrial membrane, J. Membr. Biol. 104 (1988), 193-209.
45. G. Lenaz, R. Fato, C. Castelluccio, M. Battino, M. Cavazzoni, H. Rauchova and G.P. Castelli, Coenzyme Q saturation kinetics of mitochondrial enzymes: theory, experimental aspects and biomedical implications, in: Biomedical and Clinical Aspects of Coenzyme Q, K. Folkers, T. Yamagami and G.P. Littarru, eds, Vol. 6, Elsevier, Amsterdam, 1991, pp. 11-18.
46. A.W. Linnane, C. Zhang, A. Baumer and P. Nagley, Mitochondrial DNA mutation and the aging process: bioenergy and pharmacological intervention, Mutation Research 275 (1992), 195-208.
47. 10 in human heart disease. Part I and II, Internat. J. Vit. Nutr. Res. 42(2) (1972), 291; 42(3), 413.
48. 10 in human heart disease. Part I and II, Internat. J. Vit. Nutr. Res. 42(2) (1972), 291; 42(3), 413.
49. 10 putatively acting through the plasma membrane oxidase, Biochem. Mol. Biol. Internat. 31 (1993), 997-1005.
50. P. Mitchell, Possible molecular mechanism of the protonmotive function of cytochrome systems, J. Theor. Biol. 62 (1976), 327-367.
51. 10 in borderline hypertensive patients: a hemodynamic study, in: Biomedical and Clinical Aspects of Coenzyme Q, Vol. 6, Elsevier, Amsterdam, 1991, pp. 417-424.
52. 10 therapy in patients with congestive heart failure: a long-term multicenter randomized study, K. Folkers, S.A. Mortensen, G.P. Littarru, T. Yamagami and G. Lenaz, guest eds, Clinical Investigator 71(Suppl. 8) (1993), S134-S136.
53. 10 treatment, Molecular Aspects of Medicine 15(Suppl.) (1994), s155-s163.
54. 10 therapy: a major advance in the management of resistant myocardial failure, Drugs Exp. Clin. Res. 11(8) (1985), 581-593.
55. 10 withdrawal, in: Biomedical and Clinical Aspects of Coenzyme Q, K. Folkers and Y. Yamamura, eds, Vol. 5, Elsevier, Amsterdam, 1986, pp. 281-290.
56. 10: clinical benefits with biochemical correlates suggesting a scientific breakthrough in the management of chronic heart failure, Int. J. Tissue React. 12(3) (1990), 155-162.
57. 10 during treatment with HMG-CoA reductase inhibitors, Molecular Aspects of Medicine 18(Suppl.) (1997), s137-s144.
58. R.A. Morton, G.M. Wilson, J.S. Lowe and W.M.F. Leat, Ubiquinone, in: Chemical Industry, 1957, p. 1649.
59. M. Nagano, M. Saito, S. Mochizuki, S. Anazawa, S. Tomizuka, M. Kawamura and H. Aoki, J. Adult Dis. 6, 281-286 (in Japanese).
60. 10 to the inner membrane of heart mitochondria in rats, in: Biomedical and Clinical Aspects of Coenzyme Q, K. Folkers and Y. Yamamura, eds, Vol. 2, Elsevier, North-Holland Press, 1981, pp. 3-14.
61. 10 on load-induced cardiac dysfunction: double blind study and investigation of dose-response relationship, in: Highlights in Ubiquinone Research, G. Lenaz, O. Barnabei, A. Rabbi and M. Battino, eds, Taylor and Francis, London, 1990, pp. 232-237.
62. 10 in patients with load-induced contractility depression, Molecular Aspects of Medicine 15(Suppl.) (1994), 149-154.
63. T. Ozawa, Formation of oxygen radicals in the electron transfer chain and antioxidant properties of coenzyme Q, in: Coenzyme Q. Biochemistry, Bioenergetics and Clinical Applications of Ubiquinone, G. Lenaz, ed., John Wiley & Sons, 1985, Chapter XXI, pp. 441-456.
64. A. Palomaki, K. Malminiemi and T. Metsä-Ketalä, Enhanced oxidizability of ubiquinol and alpha-tocopherol during lovastatin treatment, FEBS Letter 410(2,3) (1997), 254-258.
65. 10) in the long-term treatment of idiopathic dilated cardiomyopathy, European Heart J. 13(11) (1992), 1528-1533.
66. 10 on left ventricular function in patients with dilative cardiomyopathy. A medium-term randomized double-blind study versus placebo, Current Therapeutic Research 49(5) (1991), 878-886.
67. F. Rengo, P. Abete, P. Landino, D. Leosco, F. Covelluzzi, D. Vitale, N. Ferrara et al., Role of metabolic therapy in cardiovascular disease, K. Folkers, S.A. Mortensen, G.P. Littarru, T. Yamagami and G. Lenaz, guest eds, The Clinical Investigator 71 (1993), S124-S128.
68. 10, in: Biomedical and Clinical Aspects of Coenzyme Q, Vol. 3, Elsevier, Amsterdam, 1981, pp. 229-234.
69. 10 in ischaemic cardiopathy, in: Biomedical and Clinical Aspects of Coenzyme Q, K. Folkers, T. Yamagami and G.P. Littarru, eds, Vol. 6, Elsevier, Amsterdam, 1991, pp. 321-326.
70. H. Rudney, A.M.D. Nambudiri and S. Ranganathan, The regulation of the synthesis of coenzyme Q in fibroblasts and in heart muscle, in: Biomedical and Clinical Aspects of Coenzyme Q, K. Folkers and Y. Yamamura, eds, Vol. 3, Elsevier, North-Holland Press, 1981, pp. 279-290.
71. 10 on ischaemia-induced ST-segment depression: a double blind, placebo-controlled crossover study, in: Biomedical and Clinical Aspects of Coenzyme Q, K. Folkers, T. Yamagami and G.P. Littarru, eds, Vol. 6, Elsevier, Amsterdam, 1986, pp. 385-403.
72. 10 on patiens with cardiac disease, in: Biomedical and Clinical Aspects of Coenzyme Q, K. Folkers and Y. Yamamura, eds, Vol. 5, Elsevier, Amsterdam, 1986, pp. 325-333.
73. 10 in patients with moderate heart failure and chronic stable effort angina, in: Biomedical and Clinical Aspects of Coenzyme Q, K. Folkers, T. Yamagami and G.P. Littarru, eds, Vol. 6, Elsevier, Amsterdam, 1991, pp. 327-338.
74. 10 illuminated by meta-analyses of clinical trials, Molecular Aspects of Medicine 18(Suppl.) (1997), S159-S168.
75. 10 to enhance intraoperative myocardial protection in coronary artery revascularization, Cardiovasc. Drugs Ther. 2(Suppl.) (1991), 297-300.
76. 10 as an adjunctive in treatment of congestive heart failure, J. Cardiac Failure 1 (1995), 101-107.
77. 10 on myocardial protection during cardiac operations, Annals of Thoracic Surgery 61(3) (1996), 829-833.
78. 10: the prophylactic effect on low cardiac output following cardiac valve replacement, Annals of Thoracic Surgery 33(2) (1982), 145-151.
79. S.R. Thomas, J. Neuzil and R. Stocker, Cosupplementation with coenzyme Q prevents the prooxidant effect of alpha-tocopherol and increases the resistance of LDL to transition metal-dependent oxidation initiation, Arterioscler. Thromb. Vasc. Biol. 16(5) (1996), 687-696.
80. S.R. Thomas, J. Neuzil and R. Stocker, Inhibition of LDL oxidation by ubiquinol-10. A protective mechanisms for coenzyme Q in atherogenesis?, Molecular Aspects of Medicine 18(Suppl.) (1997), s85-s103.
81. T. Tsuyuasaki, C. Noro and R. Kikawada, Mechanocardiography of ischemic or hypertensive heart disease, in: Biomedical and Clinical Aspects of Coenzyme Q, Y. Yamamura and K. Folkers, eds, Vol. 2, Elsevier, Amsterdam, 1980, pp. 273-288.
82. 10 on physical performance and recovery in myocardial failure, in: Biomedical and Clinical Aspects of Coenzyme Q, K. Folkers and Y. Yamamura, eds, Vol. 5, Elsevier, Amsterdam, 1986, pp. 371-377.
83. 5 reductase on the antioxidant function of coenzyme Q in the plasma membrane, G.P. Littarru, M. Alleva, M. Battino and K. Folkers, guest eds, Molecular Aspects of Medicine 18(Suppl.) (1997), s7-s13.
84. R.A. Willis, K. Folkers, J.L. Tucker, C.Q. Ye, L.J. Xia and H. Tamagawa, Lovastatin decreases coenzyme Q levels in rats, Proceedings of the National Academy of Sciences USA 87(22) (1990), 8928-8930.
85. 10 therapy and exercise duration in stable angina, in: Biomedical and Clinical Aspects of Coenzyme Q, K. Folkers, G.P. Littarru and T. Yamagami, eds, Vol. 6, Elsevier, Amsterdam, 1991, pp. 339-348.
86. 10 in essential hypertension, in: Biomedical and Clinical Aspects of coenzyme Q, K. Folkers and Y. Yamamura, eds, Elsevier, Amsterdam, 1977, pp. 231-242.
87. 10 on essential hypertension, a double blind controlled study, in: Biomedical and Clinical Aspects of Coenzyme Q, Vol. 5, Elsevier, Amsterdam, 1986, pp. 337-343.
88. Y. Yamamura, Jpn. Circ. J. 31 (1967), 168.
89. Y. Yamamura, T. Ishiyama, Y. Morita and T. Yamagami, Sogo Rinsho 16 (1967), 1564-1572 (in Japanese).
90. Y. Yamamura, T. Ishiyama, Y. Morita, N. Tsukamoto, J. Kobayashi and T. Yamagami, Sogo Rinsho (Clinic All-round) 17 (1968), 1057-1065 (in Japanese).
91. Y. Yamamura, Clinical status of coenzyme Q and prospects, in: Biomedical and Clinical Aspects of Coenzyme Q, K. Folkers and Y. Yamamura, eds, Elsevier, Amsterdam, 1977, pp. 281-298.
92. Y. Yamamura, A survey of the therapeutic uses of coenzyme Q, in: Coenzyme Q. Biochemistry, Bioenergetics and Clinical Applications of Ubiquinone, G. Lenaz, ed., John Wiley & Sons, 1985, pp. 479-505.
93. 10 protects coronary endothelial function from ischemia reperfusion injury via an antioxidant effect, Surgery 120(2) (1996), 189-196.